Please assess the completion status of the following clinical trial:

Trial Title: Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* male or female, ages between 8 and 17~* Body Mass Index \> 30~* fasting blood sugar between 90-100 mg/dl~* 2 hour post prandial \>140 \<180 mg/dl~* meets criteria for a diagnosis of ADHD, any subtype~Exclusion Criteria:~* known cardiovascular disease or diabetes~* structural cardiac abnormalities, abnormal ECGs, family history of sudden death~* positive urine drug screen~* fasting blood sugar level \> 126 mg/dl~* HbA1c \> 6.5 %~* Weight \> 300 lbs

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Open label Vyvanse (Type: ACTIVE_COMPARATOR): Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.

Based on this trial design, predict the completion outcome and termination type (if applicable).